Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease

ent increase in GCase levels was observed in white blood cells from healthy volunteers receiving Plicera.

Phase 2 Clinical Trials of Plicera in Gaucher Disease

Based on the Phase 1 results, Amicus has initiated two Phase 2 clinical trials of Plicera for Gaucher disease. One is a 4-week study designed to evaluate the safety and pharmacodynamic effects of Plicera in Type I Gaucher patients who will discontinue enzyme replacement therapy for the duration of the study. The second is a 6-month study designed to evaluate the safety of Plicera and its effect on parameters that are commonly abnormal in Gaucher disease. This study will be conducted in Type I Gaucher patients who have never received enzyme replacement therapy. More information regarding these studies can be found at www.clinicaltrials.gov and www.amicustherapeutics.com.

About Gaucher Disease

Gaucher disease, the most commonly diagnosed lysosomal storage disorder, is caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system. Gaucher disease affects an estimated 8,000 to 10,000 people worldwide. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:5/28/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... buyers to divest in the United States ... Biomet Discovery® Elbow System assets and Cobalt™ bone cement ... pending acquisition of Biomet, Inc. ("Biomet").  , ... with the Bureau of Competition Staff of the U.S. ...
(Date:5/28/2015)... NEW YORK , May 28, 2015 ... billions developing new drugs and tests, and ... for the instruments that can assist them. This ... research publisher. Kalorama Information said instruments such as ... can assist in the identification of drug ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
Breaking Medicine Technology:Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
(Date:5/28/2015)... 2015 The Clinical Data Interchange ... the International Organization for Standardization (ISO) now recognizes ... Model version 3.2 as a published, Final International ... healthcare. This standard, which had previously passed through ... unanimously approved on 24 April for publication by ...
(Date:5/28/2015)... The Boys & Girls Club of Atlantic ... Cross Blue Shield of New Jersey (Horizon BCBSNJ) and through ... can receive much more support as play begins for the ... Boys & Girls Club member and volunteer with the organization ... has accepted the Horizon Blue Cross Blue Shield of New ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Are policies ... after a hospital stay triggering financial pain for seniors? ... American Journal of Managed Care set to figure out, ... recent federal rule change. , The study, “Observation Encounters ... A. Vashi, MD, MPH, examined how Medicare policies that ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital ... Sicilian economy by €132.5 million in expenditure in 2013, generated ... than €73 million by retaining patients who otherwise would have ... study by the Battelle Memorial Institute. At the same time, ... advanced health care management that is transforming Sicily into a ...
(Date:5/28/2015)... 2015 Workers’ compensation costs per claim in ... recent study by the Workers Compensation Research Institute ... period. , The WCRI study, CompScope™ Benchmarks for Michigan, ... seven days or more of work with those of 16 ... Michigan claim was 4 percent lower than similar claims from ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2
... , , HARRISBURG, Pa., July ... received free dental care, valued at nearly $160,000, in the ... United Concordia Dental. , , ... provide free preventive services to those who cannot afford dental ...
... , INDIANAPOLIS, July 23 Today, ... that the U.S. Food and Drug Administration (FDA) has approved ... origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid ... Glucocorticoid therapy is the most common cause of secondary osteoporosis, ...
... Cancer stem-like cells have been implicated in the ... at Cedars-Sinai Medical Center,s Maxine Dunitz Neurosurgical Institute have ... these "mother" cells to generate new tumors in laboratory ... a possible strategy in the fight against malignant and ...
... , , , , ... Program (NCDP), a program of Novo Nordisk, and several member associations today ... and treatment of diabetes, one of the nation,s most pervasive and costly ... , In an open letter to the President and ...
... , , SAN DIEGO, ... ) today announced that it has priced an underwritten public ... price of $7.50 per share. Net proceeds, after estimated underwriting ... million. Orexigen has granted the underwriter a 30-day option to ...
... 23 At the 2009 American Association of Physicists ... California, Elekta will demonstrate how the company,s comprehensive VMAT ... care with precision and ease. , , ... radiation treatments, Elekta booth 423 will highlight treatment planning ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 2Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 3Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3
Reusable shielded cable...
... A OIA MAX test delivers excellent sensitivity ... Strep with a simple, easy-to-use test that ... of performance, speed, and ease-of-use enables you ... overall costs for diagnosing and treating patients ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
Medicine Products: